医药行业首份三季报公布!营收41.61亿元,九洲药业求稳容易求爆发难?

医药研究社
Oct 17

转眼三个季度过去,药企又到了披露成绩单的关键节点。10月15日,我们也等来了今年医药生物行业(按申万行业分类)首份三季报,来自CDMO(合同研发生产组织)企业九洲药业。九洲药业最新发布的财报显示,前三季度,公司共实现营业收入41.61亿元,同比增长4.92%;归属于上市公司股东的净利润7.48亿元,同比增长18.51%。这样一份增长信号十分突出的答卷,可以说给后续医药行业三季报的集中公布开了一个...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10